Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 17/20 | 0.56 |
| ▸ | ESR1 | P03372 | 5/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14117545 | 1.00 | ESR2 (0.56) | ESR2ESR1CYP3A4CYP2C9HDAC2 | |
| SCHEMBL4600001 | 0.87 | AKR1C3 (0.44) | ESR2DEGS1 | |
| SCHEMBL14117526 | 0.87 | AKR1C3 (0.44) | ESR2DEGS1 | |
| SCHEMBL4600748 | 0.86 | HSD11B1 (0.46) | ESR2ESR1CYP2C9DEGS1 | |
| SCHEMBL4601341 | 0.86 | ESR2 (0.45) | ESR2ESR1CYP3A4CYP2C9 | |
| SCHEMBL27579808 | 0.83 | ESR2 (0.41) | ESR2ESR1 | |
| SCHEMBL27595976 | 0.82 | ESR2 (0.41) | ESR2ESR1CYP3A4CYP2C9 | |
| SCHEMBL296142 | 0.82 | ALDH1A1 (0.44) | ESR2 | |
| SCHEMBL14220686 | 0.79 | KMT2A (0.50) | — | |
| SCHEMBL4601079 | 0.79 | KMT2A (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100491396-C | Selective cyclic peptides | HOFFMANN LA ROCHE (CH) | 2009-05-27 | — | — | CN | disclosed |
| US-20080177036-A1 | Selective Linear Peptides with Melanocortin-4 Receptor (MC4-R) Agonist Activity | CHEN LI | 2008-07-24 | — | — | US | disclosed |
| EP-1272516-B1 | SELECTIVE LINEAR PEPTIDES WITH MELANOCORTIN-4 RECEPTOR (MC4-R) AGONIST ACTIVITY | HOFFMANN LA ROCHE (CH) | 2008-04-23 | — | — | EP | disclosed |
| EP-1315750-B1 | CYCLIC PEPTIDES HAVING MELANOCORTIN-4 RECEPTOR AGONIST ACTIVITY | HOFFMANN LA ROCHE (CH) | 2007-02-14 | — | — | EP | disclosed |
| US-7045591-B2 | Selective cyclic peptides with melanocortin-4 receptor (MC4-R) agonist activity | HOFFMANN-LA ROCHE INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20050239711-A1 | Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity | CHEN LI | 2005-10-27 | — | — | US | disclosed |
| US-20030229200-A1 | Selective linear peptides with melanocor tin-4 receptor (MC4-R) agonist activity | CHEN LI (US) | 2003-12-11 | — | — | US | disclosed |
| CN-1451017-A | Selective cyclic peptides | HOFFMANN LA ROCHE (CH) | 2003-10-22 | — | — | CN | disclosed |
| US-6600015-B2 | Treatment or prevention of obesity. | HOFFMANN-LA ROCHE INC. | 2003-07-29 | — | — | US | disclosed |
| EP-1272516-A2 | SELECTIVE LINEAR PEPTIDES WITH MELANOCORTIN-4 RECEPTOR (MC4-R) AGONIST ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-08 | — | — | EP | disclosed |
| US-20020143141-A1 | Selective cyclic peptides with melanocortin-4 receptor (MC4-R) agonist activity | CHEN LI (US) | 2002-10-03 | — | — | US | disclosed |
| US-20010056179-A1 | Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity | HOFFMANN-LA ROCHE INC. | 2001-12-27 | — | — | US | disclosed |
| WO-2001074844-A2 | SELECTIVE LINEAR PEPTIDES WITH MELANOCORTIN-4 RECEPTOR (MC4-R) AGONIST ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080177036-A1 | Selective Linear Peptides with Melanocortin-4 Receptor (MC4-R) Agonist Activity | MC4R, MC3R, MC1R | ESR2 1159/4885ESR1 1579/4885CYP3A4 1800/4885 |
| US-20020143141-A1 | Selective cyclic peptides with melanocortin-4 receptor (MC4-R) agonist activity | MC4R, MC3R, MC1R | ESR2 1272/4885ESR1 1438/4885CYP3A4 1816/4885 |
| US-20050239711-A1 | Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity | MC4R, MC3R, MC1R | ESR2 1159/4885ESR1 1579/4885CYP3A4 1800/4885 |
| US-20030229200-A1 | Selective linear peptides with melanocor tin-4 receptor (MC4-R) agonist activity | MC4R, MC1R, MC3R | ESR2 759/4885ESR1 1005/4885CYP3A4 1637/4885 |
| US-20010056179-A1 | Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity | MC4R, MC3R, MC1R | ESR2 1169/4885ESR1 1561/4885CYP3A4 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.